Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nong Yang

Showing results (131-140 of 209) with videos related to

Pageof 21
Sort By:
Cancer Medicine|February 27, 2020
Postoperative intensity-modulated radiation therapy reduces local recurrence and improves overall survival in III-N2 non-small-cell lung cancer: A single-center, retrospective studyWei Wei, Jiao Zhou, Qun Zhang, et al.
Mayo Clinic Proceedings. Innovations, Quality & Outcomes|October 3, 2022
A Novel Inflammation-Based Risk Score Predicts Mortality in Acute Type A Aortic Dissection Surgery: The Additive Anti-inflammatory Action for Aortopathy and Arteriopathy ScoreHong Liu, Si-Chong Qian, Ying-Yuan Zhang, et al.
Innovation (Cambridge (Mass.))|January 3, 2022
Profiling of immune features to predict immunotherapy efficacyYouqiong Ye, Yongchang Zhang, Nong Yang, et al.
The Lancet. Respiratory Medicine|June 6, 2022
Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 studyYuankai Shi, Gongyan Chen, Xiang Wang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 6, 2022
Central Nervous System Efficacy of Furmonertinib (AST2818) Versus Gefitinib as First-Line Treatment for EGFR-Mutated NSCLC: Results From the FURLONG StudyYuankai Shi, Gongyan Chen, Xiang Wang, et al.
Genome Medicine|September 29, 2020
Small-molecule MMP2/MMP9 inhibitor SB-3CT modulates tumor immune surveillance by regulating PD-L1Youqiong Ye, Xinwei Kuang, Zuozhong Xie, et al.
The Lancet Regional Health. Western Pacific|July 12, 2024
Patient-reported outcomes for the phase 3 FURLONG study of furmonertinib versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic <i>EGFR</i> mutation-positive non-small cell lung cancerYuankai Shi, Gongyan Chen, Xiang Wang, et al.
Future Oncology (London, England)|March 6, 2023
TRUST-II: a global phase II study of taletrectinib in <i>ROS1</i>-positive non-small-cell lung cancer and other solid tumorsMisako Nagasaka, Yuichiro Ohe, Caicun Zhou, et al.
Iscience|August 20, 2025
Lymphocyte subset-based non-invasive biomarker predicts immunochemotherapy efficacy in EGFR-TKI-pretreated EGFR-mutated NSCLCLianxi Song, Liang Zeng, Qinqin Xu, et al.
Ebiomedicine|February 21, 2025
Overall survival according to time-of-day of combined immuno-chemotherapy for advanced non-small cell lung cancer: a bicentric bicontinental studyZhe Huang, Abdoulaye Karaboué, Liang Zeng, et al.
Pageof 21

Showing results (131-140 of 209) with videos related to

Sort By:
Pageof 21
Cancer Medicine|February 27, 2020
Postoperative intensity-modulated radiation therapy reduces local recurrence and improves overall survival in III-N2 non-small-cell lung cancer: A single-center, retrospective studyWei Wei, Jiao Zhou, Qun Zhang, et al.
Mayo Clinic Proceedings. Innovations, Quality & Outcomes|October 3, 2022
A Novel Inflammation-Based Risk Score Predicts Mortality in Acute Type A Aortic Dissection Surgery: The Additive Anti-inflammatory Action for Aortopathy and Arteriopathy ScoreHong Liu, Si-Chong Qian, Ying-Yuan Zhang, et al.
Innovation (Cambridge (Mass.))|January 3, 2022
Profiling of immune features to predict immunotherapy efficacyYouqiong Ye, Yongchang Zhang, Nong Yang, et al.
The Lancet. Respiratory Medicine|June 6, 2022
Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 studyYuankai Shi, Gongyan Chen, Xiang Wang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 6, 2022
Central Nervous System Efficacy of Furmonertinib (AST2818) Versus Gefitinib as First-Line Treatment for EGFR-Mutated NSCLC: Results From the FURLONG StudyYuankai Shi, Gongyan Chen, Xiang Wang, et al.
Genome Medicine|September 29, 2020
Small-molecule MMP2/MMP9 inhibitor SB-3CT modulates tumor immune surveillance by regulating PD-L1Youqiong Ye, Xinwei Kuang, Zuozhong Xie, et al.
The Lancet Regional Health. Western Pacific|July 12, 2024
Patient-reported outcomes for the phase 3 FURLONG study of furmonertinib versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic <i>EGFR</i> mutation-positive non-small cell lung cancerYuankai Shi, Gongyan Chen, Xiang Wang, et al.
Future Oncology (London, England)|March 6, 2023
TRUST-II: a global phase II study of taletrectinib in <i>ROS1</i>-positive non-small-cell lung cancer and other solid tumorsMisako Nagasaka, Yuichiro Ohe, Caicun Zhou, et al.
Iscience|August 20, 2025
Lymphocyte subset-based non-invasive biomarker predicts immunochemotherapy efficacy in EGFR-TKI-pretreated EGFR-mutated NSCLCLianxi Song, Liang Zeng, Qinqin Xu, et al.
Ebiomedicine|February 21, 2025
Overall survival according to time-of-day of combined immuno-chemotherapy for advanced non-small cell lung cancer: a bicentric bicontinental studyZhe Huang, Abdoulaye Karaboué, Liang Zeng, et al.
Pageof 21